Novartis Cancer Drug Trial Doesn't Meet Primary Endpoints
October 25 2021 - 1:58AM
Dow Jones News
By Cecilia Butini
Novartis AG said Monday that a Phase 3 trial to evaluate a drug
for use in lung cancer patients didn't meet its primary
endpoints.
The Swiss pharma major said the trial, named CANOPY-1, didn't
demonstrate statistical significance in overall survival and
progression-free survival, meaning the time that a patient can live
without the disease progressing.
The trial evaluated canakinumab, a monoclonal antibody, in
combination with chemotherapy for patients with non-small cell lung
cancer.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 25, 2021 01:43 ET (05:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
